Table A2.
All of the detailed parameters of target cytokines decreased or increased among experimental groups.
| Coordinate | Target | Fold | |
|---|---|---|---|
| db/db (vs.db/m+) | db/db+100 mg/kg PTA (vs.db/db) | ||
| A 3; A 4 | Adiponectin/Acrp30 | −24.8% | −0.4% |
| A 5; A 6 | Amphiregulin | 18.6% | −6.7% |
| A 7; A 8 | Angiopoietin-1 | 15.0% | −3.9% |
| A 9; A 10 | Angiopoietin-2 | 29.8% | 3.4% |
| A 11; A 12 | Angiopoietin-like 3 | 43.6% | −7.8% |
| A 13; A 14 | BAFF/BLyS/TNFSF13B | −1.9% | 21.2% |
| A 15; A 16 | C1q R1/CD93 | 14.1% | 9.9% |
| A 17; A 18 | CCL2/JE/MCP-1 | −3.6% | 30.9% |
| A 19; A 20 | CCL3/CCL4 MIP-1 alpha/beta | 0.7% | 13.9% |
| A 21; A 22 | CCL5/RANTES | −6.0% | −12.3% |
| B 3; B 4 | CCL6/C10 | 31.9% | −17.4% |
| B 5; B 6 | CCL11/Eotaxin | 23.3% | −5.9% |
| B 7; B 8 | CCL12/MCP-5 | 12.7% | −9.8% |
| B 9; B 10 | CCL17/TARC | 17.1% | −11.0% |
| B 11; B 12 | CCL19/MIP-3 beta | 3.2% | 1.9% |
| B 13; B 14 | CCL20/MIP-3 alpha | −12.6% | 13.9% |
| B 15; B 16 | CCL21/6Ckine | 3.2% | 0.9% |
| B 17; B 18 | CCL22/MDC | −3.4% | 20.2% |
| B 19; B 20 | CD14 | 5.5% | 11.1% |
| B 21; B 22 | CD40/TNFRSF5 | 29.0% | −11.6% |
| C 3; C 4 | CD160 | 8.9% | 5.7% |
| C 5; C 6 | Chemerin | 20.7% | −5.1% |
| C 7; C 8 | Chitinase 3-like 1 | 187.7% | −60.1% |
| C 9; C 10 | Coagulation Factor III/ Tissue Factor | −4.9% | −1.2% |
| C 11; C 12 | Complement Component C5/C5a | −7.6% | 1.7% |
| C 13; C 14 | Complement Factor D | −60.4% | 17.6% |
| C 15; C 16 | C-Reactive Protein/CRP | 44.5% | −8.6% |
| C 17; C 18 | CX3CL1/Fractalkine | −20.9% | 6.8% |
| C 19; C 20 | CXCL1/KC | 2.4% | 7.6% |
| C 21; C 22 | CXCL2/MIP-2 | 11.3% | 6.9% |
| D 1; D 2 | CXCL9/MIG | 4.8% | −25.2% |
| D 3; D 4 | CXCL10/IP-10 | 8.7% | −20.1% |
| D 5; D 6 | CXCL11/I-TAC | −0.3% | −6.8% |
| D 7; D 8 | CXCL13/BLC/BCA-1 | 31.4% | −28.2% |
| D 9; D 10 | CXCL16 | 20.5% | −6.3% |
| D 11; D 12 | Cystatin C | −1.0% | −6.7% |
| D 13; D 14 | DKK-1 | −8.5% | 16.9% |
| D 15; D 16 | DPPIV/CD26 | −13.1% | 3.0% |
| D 17; D 18 | EGF | −4.5% | −3.2% |
| D 19; D 20 | Endoglin/CD105 | −6.2% | −2.3% |
| D 21; D 22 | Endostatin | 3.2% | −9.9% |
| D 23; D 24 | Fetuin A/AHSG | −11.2% | −16.1% |
| E 1; E 2 | FGF acidic | −2.6% | −2.9% |
| E 3; E 4 | FGF-21 | −7.4% | −5.0% |
| E 5; E 6 | Flt-3 Ligand | −6.4% | 1.8% |
| E 7; E 8 | Gas 6 | 9.7% | −7.1% |
| E 9; E 10 | G-CSF | 2.7% | 7.0% |
| E 11; E 12 | GDF-15 | 4.5% | 18.4% |
| E 13; E 14 | GM-CSF | −8.8% | 19.0% |
| E 15; E 16 | HGF | −16.4% | 26.5% |
| E 17; E 18 | ICAM-1/CD54 | −10.9% | 1.1% |
| E 19; E 20 | IFN-gamma | −14.9% | 45.9% |
| E 21; E 22 | IGFBP-1 | 32.6% | −2.9% |
| E 23; E 24 | IGFBP-2 | −53.4% | −2.0% |
| F 1; F 2 | IGFBP-3 | −3.0% | 4.9% |
| F 3; F 4 | IGFBP-5 | −4.3% | 4.5% |
| F 5; F 6 | IGFBP-6 | −11.0% | −5.2% |
| F 7; F 8 | IL-1 alpha/IL-1F1 | 5.0% | −1.8% |
| F 9; F 10 | IL-1 beta/ IL-1F2 | 17.8% | −10.7% |
| F 11; F 12 | IL-1ra/IL-1F3 | 58.9% | −31.1% |
| F 13; F 14 | IL-2 | 19.2% | 0.4% |
| F 15; F 16 | IL-3 | −9.8% | 12.1% |
| F 17; F 18 | IL-4 | −25.4% | 18.2% |
| F 19; F 20 | IL-5 | −0.7% | −10.7% |
| F 21; F 22 | IL-6 | 32.4% | 0.7% |
| F 23; F 24 | IL-7 | 4.4% | −8.8% |
| G 1; G 2 | IL-10 | 6.0% | 3.9% |
| G 3; G 4 | IL-11 | −4.1% | 8.2% |
| G 5; G 6 | IL-12p40 | 3.6% | 6.4% |
| G 7; G 8 | IL-13 | 8.6% | −4.4% |
| G 9; G 10 | IL-15 | 17.8% | −12.5% |
| G 11; G 12 | IL-17A | 22.4% | 12.9% |
| G 13; G 14 | IL-22 | 5.3% | −2.2% |
| G 15; G 16 | IL-23 | 0.3% | 3.1% |
| G 17; G 18 | IL-27p28 | −8.5% | 0.7% |
| G 19; G 20 | IL-28 | −10.8% | −1.9% |
| G 21; G 22 | IL-33 | 20.7% | 26.1% |
| G 23; G 24 | LDL R | 9.6% | −2.5% |
| H 1; H 2 | Leptin | 156.9% | −14.2% |
| H 3; H 4 | LIF | 11.9% | −17.0% |
| H 5; H 6 | Lipocalin-2/NGAL | 97.3% | −34.9% |
| H 7; H 8 | LIX | 31.5% | −29.8% |
| H 9; H 10 | M-CSF | 21.6% | −11.2% |
| H 11; H 12 | MMP-2 | 20.1% | −18.8% |
| H 13; H 14 | MMP-3 | 24.6% | −25.1% |
| H 15; H 16 | MMP-9 | 64.0% | −33.7% |
| H 17; H 18 | Myeloperoxidase | 83.5% | −49.4% |
| H 19; H 20 | Osteopontin (OPN | 62.5% | −17.2% |
| H 21; H 22 | Osteoprotegerin/ TNFRSF11B | 13.2% | −14.3% |
| H 23; H 24 | PD-ECGF/ Thymidine phosphorylase | 13.7% | −2.1% |
| I 1; I 2 | PDGF-BB | 21.4% | −36.0% |
| I 3; I 4 | Pentraxin 2/SAP | 14.3% | −15.2% |
| I 5; I 6 | Pentraxin 3/ TSG-14 | 21.5% | −17.7% |
| I 7; I 8 | Periostin/OSF-2 | 42.9% | −16.2% |
| I 9; I 10 | Pref-1/DLK-1/FA1 | 28.1% | −19.2% |
| I 11; I 12 | Proliferin | 16.8% | −3.7% |
| I 13; I 14 | Proprotein Convertase 9/ PCSK9 | 3.5% | −26.6% |
| I 15; I 16 | RAGE | 16.6% | −16.2% |
| I 17; I 18 | RBP4 | 15.4% | −28.8% |
| I 19; I 20 | Reg3G | 13.9% | −11.2% |
| I 21; I 22 | Resistin | −39.9% | −0.5% |
| J 3; J 4 | E-Selectin/CD62E | 7.8% | −23.9% |
| J 5; J 6 | P-Selectin/CD62P | −14.3% | −7.8% |
| J 7; J 8 | Serpin E1/PAI-1 | 20.4% | −27.4% |
| J 9; J 10 | Serpin F1/PEDF | 4.1% | −29.5% |
| J 11; J 12 | Thrombopoietin | 17.0% | −12.3% |
| J 13; J 14 | TIM-1/KIM-1/ HAVCR | 388.0% | −62.9% |
| J 15; J 16 | TNF-alpha | 32.0% | −24.4% |
| J 17; J 18 | VCAM-1/CD106 | 28.3% | −30.9% |
| J 19; J 20 | VEGF | −3.9% | −11.7% |
| J 21; J 22 | WISP-1/CCN4 | −2.2% | −18.9% |